<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "10: expenses associated with operations outside", fill: "#e32636"},
{source: "10: expenses associated with operations outside", target: "10: operations", fill: "#e32636"},
{source: "10: operations", target: "10: United States ", fill: "#e32636"},
{source: "10: United States ", target: "10: historically", fill: "#e32636"},
{source: "10: historically", target: "10: been relatively higher as", fill: "#e32636"},
{source: "10: been relatively higher as", target: "10: United States and Canada", fill: "#e32636"},
{source: "10: expenses associated with operations outside", target: "14: independently", fill: "#ba55d3"},
{source: "14: independently", target: "14: collaboration with others various products", fill: "#ba55d3"},
{source: "14: collaboration with others various products", target: "14: address poultry health", fill: "#ba55d3"},
{source: "14: independently", target: "15: conjunction with", fill: "#ff6347"},
{source: "15: conjunction with", target: "15: various stages", fill: "#ff6347"},
{source: "15: various stages", target: "15: development", fill: "#ff6347"},
{source: "15: conjunction with", target: "18: regulatory approval process", fill: "#e5e4e2"},
{source: "18: regulatory approval process", target: "18: cannot assure", fill: "#e5e4e2"},
{source: "18: cannot assure", target: "18: regulatory approval will", fill: "#e5e4e2"},
{source: "18: regulatory approval process", target: "21: development", fill: "#b06500"},
{source: "21: development", target: "21: evaluations", fill: "#b06500"},
{source: "21: evaluations", target: "21: new technologies may", fill: "#b06500"},
{source: "21: new technologies may", target: "21: yield product opportunities", fill: "#b06500"},
{source: "21: yield product opportunities", target: "21: potential product", fill: "#b06500"},
{source: "21: potential product", target: "21: products may", fill: "#b06500"},
{source: "21: products may", target: "21: timeconsuming clinical", fill: "#b06500"},
{source: "21: timeconsuming clinical", target: "21: demonstrate safety", fill: "#b06500"},
{source: "21: demonstrate safety", target: "21: effectiveness", fill: "#b06500"},
{source: "21: effectiveness", target: "21: collaborative partners", fill: "#b06500"},
{source: "21: collaborative partners", target: "21: enter into arrangements on terms", fill: "#b06500"},
{source: "21: enter into arrangements on terms", target: "21: manufacture", fill: "#b06500"},
{source: "21: manufacture", target: "21: products at", fill: "#b06500"},
{source: "21: products at", target: "21: quantities necessary", fill: "#b06500"},
{source: "21: quantities necessary", target: "21: commercially viable", fill: "#b06500"},
{source: "21: commercially viable", target: "21: international regulatory approval", fill: "#b06500"},
{source: "21: international regulatory approval", target: "21: only with lengthy delays", fill: "#b06500"},
{source: "21: only with lengthy delays", target: "21: secure additional financing", fill: "#b06500"},
{source: "21: secure additional financing", target: "21: unexpected safety regulatory", fill: "#b06500"},
{source: "21: unexpected safety regulatory", target: "21: efficacy concerns", fill: "#b06500"},
{source: "21: efficacy concerns", target: "21: with respect", fill: "#b06500"},
{source: "21: with respect", target: "21: marketed products whether", fill: "#b06500"},
{source: "21: marketed products whether", target: "21: scientifically justified", fill: "#b06500"},
{source: "21: scientifically justified", target: "21: adverse public reaction product recalls withdrawals", fill: "#b06500"},
{source: "21: adverse public reaction product recalls withdrawals", target: "21: declining sales", fill: "#b06500"},
{source: "21: declining sales", target: "21: marketing products", fill: "#b06500"},
{source: "21: marketing products", target: "21: jointly with", fill: "#b06500"},
{source: "21: jointly with", target: "21: parties may", fill: "#b06500"},
{source: "21: parties may", target: "21: royalty payments", fill: "#b06500"},
{source: "21: royalty payments", target: "21: payments by us", fill: "#b06500"},
{source: "21: payments by us", target: "21: codevelopers which may", fill: "#b06500"},
{source: "21: codevelopers which may", target: "21: materially adversely affect", fill: "#b06500"},
{source: "21: materially adversely affect", target: "21: profitability", fill: "#b06500"},
{source: "21: profitability", target: "21: accurately predict market requirements", fill: "#b06500"},
{source: "21: accurately predict market requirements", target: "21: evolving standards", fill: "#b06500"},
{source: "21: evolving standards", target: "21: sufficient numbers", fill: "#b06500"},
{source: "21: sufficient numbers", target: "21: qualified development personnel", fill: "#b06500"},
{source: "21: development", target: "34: commercialized", fill: "#ffcba4"},
{source: "34: commercialized", target: "34: technology", fill: "#ffcba4"},
{source: "34: commercialized", target: "52: widespread commercial acceptance", fill: "#79443b"},
{source: "52: widespread commercial acceptance", target: "52: competing systems", fill: "#79443b"},
{source: "52: competing systems", target: "52: direct competition", fill: "#79443b"},
{source: "52: direct competition", target: "52: commercial placements", fill: "#79443b"},
{source: "52: widespread commercial acceptance", target: "60: competitors", fill: "#f3e5ab"},
{source: "60: competitors", target: "60: potential competitors", fill: "#f3e5ab"},
{source: "60: potential competitors", target: "60: independent companies", fill: "#f3e5ab"},
{source: "60: independent companies", target: "60: biotechnology as well as major agricultural", fill: "#f3e5ab"},
{source: "60: biotechnology as well as major agricultural", target: "60: animal health", fill: "#f3e5ab"},
{source: "60: animal health", target: "60: private research organizations", fill: "#f3e5ab"},
{source: "60: competitors", target: "74: proprietary", fill: "#f5f5f5"},
{source: "74: proprietary", target: "START_HERE", fill: "#f5f5f5"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Oil and Gas Refining and Marketing and Transportation</td>
    </tr>
    <tr>
      <td>Construction and Engineering</td>
    </tr>
    <tr>
      <td>Construction Materials</td>
    </tr>
    <tr>
      <td>Construction and Farm Machinery and Heavy Trucks</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States">United States</a></td>
      <td>The United States of America (U.S.A. or USA), commonly known as the United States (U.S. or US) or America, is a country primarily located in North America. It consists of 50 states, a federal district, five major unincorporated territories, 326 Indian reservations, and nine minor outlying islands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/President_of_the_United_States">President of the United States</a></td>
      <td>The president of the United States (POTUS) is the head of state and head of government of the United States of America. The president directs the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_states_and_territories_of_the_United_States">List of states and territories of the United States</a></td>
      <td>The United States of America is a federal republic consisting of 50 states, a federal district (Washington, D.C., the capital city of the United States), five major territories, and various minor islands. The 48 contiguous states and Washington, D.C., are in North America between Canada and Mexico.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Congress">United States Congress</a></td>
      <td>The United States Congress is the legislature of the federal government of the United States. It is bicameral, being composed of a lower body, the House of Representatives, and an upper body, the Senate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_presidents_of_the_United_States">List of presidents of the United States</a></td>
      <td>The president of the United States is the head of state and head of government of the United States, indirectly elected to a four-year term by the American people through the Electoral College. The office holder leads the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Republican_Party_(United_States)">Republican Party (United States)</a></td>
      <td>The Republican Party, also referred to as the GOP ("Grand Old Party"), is one of the two major contemporary political parties in the United States, along with its main historic rival, the Democratic Party.\nThe GOP was founded in 1854 by anti-slavery activists who opposed the Kansas–Nebraska Act, which allowed for the potential expansion of chattel slavery into the western territories.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_dollar">United States dollar</a></td>
      <td>The United States dollar (symbol: $; code: USD; also abbreviated US$ or U.S. Dollar, to distinguish it from other dollar-denominated currencies; referred to as the dollar, U.S. dollar, American dollar, or colloquially buck) is the official currency of the United States and several other countries. The Coinage Act of 1792 introduced the U.S. dollar at par with the Spanish silver dollar, divided it into 100 cents, and authorized the minting of coins denominated in dollars and cents.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Privately_held_company">Privately held company</a></td>
      <td>A privately held company or private company is a company which does not offer or trade its company stock (shares) to the general public on the stock market exchanges, but rather the company's stock is offered, owned and traded or exchanged privately or over-the-counter. In the case of a close corporation, there are a relatively small number of shareholders or company members.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_product_development">New product development</a></td>
      <td>In business and engineering, new product development (NPD) covers the complete process of bringing a new product to market, renewing an existing product or introducing a product in a new market. A central aspect of NPD is product design, along with various business considerations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_studies">Development studies</a></td>
      <td>Development studies is an interdisciplinary branch of social science. Development studies is offered as a specialized master's degree in a number of reputed universities around the world, such as the University of Cambridge, the London School of Economics and Political Science, King’s College London, the Institute of Development Studies at the University of Sussex, Oxford University, Harvard University, Balsillie School of International Affairs, Graduate Institute Geneva, Indian Institute of Technology Madras, SOAS London, Tata Institute of Social Sciences and University of Warwick, and less commonly, as an undergraduate degree, such as at the University of Sussex, University of Guelph, University of Toronto and McGill University.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Human_Development_Index">Human Development Index</a></td>
      <td>The Human Development Index (HDI) is a statistic composite index of life expectancy, education (mean years of schooling completed and expected years of schooling upon entering the education system), and per capita income indicators, which are used to rank countries into four tiers of human development. A country scores a higher level of HDI when the lifespan is higher, the education level is higher, and the gross national income GNI (PPP) per capita is higher.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2011_military_intervention_in_Libya">2011 military intervention in Libya</a></td>
      <td>On 19 March 2011, a multi-state NATO-led coalition began a military intervention in Libya, to implement United Nations Security Council Resolution 1973, in response to events during the First Libyan Civil War. With ten votes in favour and five abstentions, the UN Security Council's intent was to have "an immediate ceasefire in Libya, including an end to the current attacks against civilians, which it said might constitute "crimes against humanity" ...</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hardware_random_number_generator">Hardware random number generator</a></td>
      <td>In computing, a hardware random number generator (HRNG) or true random number generator (TRNG) is a device that generates random numbers from a physical process, rather than by means of an algorithm.  Such devices are often based on microscopic phenomena that generate low-level, statistically random "noise" signals, such as thermal noise, the photoelectric effect, involving a beam splitter, and other quantum phenomena.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Synchroscope">Synchroscope</a></td>
      <td>In AC electrical power systems, a synchroscope is a device that indicates the degree to which two systems (generators or power networks) are synchronized with each other.For two electrical systems to be synchronized, both systems must operate at the same frequency, and the phase angle between the systems must be zero (and two polyphase systems must have the same phase sequence). Synchroscopes measure and display the frequency difference and phase angle between two power systems.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Grasshopper_Manufacture">Grasshopper Manufacture</a></td>
      <td>Grasshopper Manufacture Inc. (株式会社グラスホッパー・マニファクチュア, Kabushiki Gaisha Gurasuhoppā Manifakuchua) is a Japanese video game developer founded on March 30, 1998 by Goichi Suda.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_d'horlogerie">Manufacture d'horlogerie</a></td>
      <td>Manufacture d'horlogerie (meaning "watchmaking manufacturer") is a French language term of horology that has also been adopted in the English language as a loanword. In horology, the term is usually encountered in its abbreviated form manufacture.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_royale">Manufacture royale</a></td>
      <td>Manufacture Royale is a Swiss luxury watch brand. Founded in the eighteenth century, the brand was revived in 2010.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_nationale_de_Sèvres">Manufacture nationale de Sèvres</a></td>
      <td>The Manufacture nationale de Sèvres is one of the principal European porcelain factories. It is located in Sèvres, Hauts-de-Seine, France.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Design_for_manufacturability">Design for manufacturability</a></td>
      <td>Design for manufacturability (also sometimes known as design for manufacturing or DFM) is the general engineering practice of designing products in such a way that they are easy to manufacture. The concept exists in almost all engineering disciplines, but the implementation differs widely depending on the manufacturing technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_company">Technology company</a></td>
      <td>A technology company (or tech company) is an electronics-based technological company, including, for example, business relating to digital electronics, software, and internet-related services, such as e-commerce services.\n\n\n== Details ==\nAccording to Fortune, as of 2020, the ten largest technology companies by revenue are: Apple Inc., Samsung, Foxconn, Alphabet Inc., Microsoft, Huawei, Dell Technologies, Hitachi, IBM, and Sony.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Educational_technology">Educational technology</a></td>
      <td>Educational technology (commonly abbreviated as edutech, or edtech) is the combined use of computer hardware, software, and educational theory and practice to facilitate learning. When referred to with its abbreviation, edtech, it is often referring to the industry of companies that create educational technology.In addition to practical educational experience, educational technology is based on theoretical knowledge from various disciplines such as communication, education, psychology, sociology, artificial intelligence, and computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_technology">Financial technology</a></td>
      <td>Financial technology (abbreviated fintech or FinTech) is the technology and innovation that aims to compete with traditional financial methods in the delivery of financial services. It is an emerging industry that uses technology to improve activities in finance.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_technology">Language technology</a></td>
      <td>Language technology, often called human language technology (HLT), studies methods of how computer programs or electronic devices can analyze, produce, modify or respond to human texts and speech. Working with language technology often requires broad knowledge not only about linguistics but also about computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Space_technology">Space technology</a></td>
      <td>Space technology is technology for use in outer space, in travel (astronautics) or other activities beyond Earth's atmosphere, for purposes such as spaceflight, space exploration, and Earth observation. Space technology includes space vehicles such as spacecraft, satellites, space stations and orbital launch vehicles; deep-space communication; in-space propulsion; and a wide variety of other technologies including support infrastructure equipment, and procedures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Proprietary_software">Proprietary software</a></td>
      <td>Proprietary software, also known as non-free software or closed-source software, is computer software for which the software's publisher or another person reserves some licensing rights to use, modify, share modifications, or share the software, restricting user freedom with the software they lease. It is the opposite of open-source or free software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_analysis">Competitor analysis</a></td>
      <td>Competitive analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors. This analysis provides both an offensive and defensive strategic context to identify opportunities and threats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Proprietary_protocol">Proprietary protocol</a></td>
      <td>In telecommunications, a proprietary protocol is a communications protocol owned by a single organization or individual.\n\n\n== Intellectual property rights and enforcement ==\nOwnership by a single organization gives the owner the ability to place restrictions on the use of the protocol and to change the protocol unilaterally.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>EMBREX INC /NC/      ITEM 1A RISK FACTORS        If any of the <font color="blue">following risks</font> occur, our business, <font color="blue">financial condition</font> or     results of <font color="blue"><font color="blue">operations</font> could</font> be <font color="blue"><font color="blue"><font color="blue">materially</font> <font color="blue">adversely</font> affect</font>ed</font></td>
    </tr>
    <tr>
      <td>OUR FUTURE GROWTH DEPENDS ON EXPANSION OF INTERNATIONAL REVENUES AND WE WILL     BE SUBJECT TO INCREASED RISKS IN THE INTERNATIONAL MARKETPLACE        We estimate that our Inovoject® system inoculates <font color="blue">approximately</font> 85prca of all     eggs produced for the <font color="blue">US and Canadian </font><font color="blue">broiler <font color="blue"><font color="blue">poultry market</font>s</font></font></td>
    </tr>
    <tr>
      <td>Given this     <font color="blue">market penetration</font>, we expect only limited growth in the number of system     <font color="blue">installations</font>  and  only  minor  <font color="blue">system <font color="blue">revenue growth</font></font> in this market</td>
    </tr>
    <tr>
      <td>Additionally, due to our <font color="blue">market penetration</font> and the significance of the US     and Canadian <font color="blue"><font color="blue">poultry market</font>s</font> to our revenue, any adverse conditions in these     <font color="blue">markets could</font> have a material and adverse effect on our revenues</td>
    </tr>
    <tr>
      <td>For this     reason, we must expand our device <font color="blue">installations</font> and <font color="blue">product sales</font> in markets     outside the <font color="blue"><font color="blue"><font color="blue">United States</font> </font>and Canada </font>in order to realize <font color="blue">revenue growth</font></td>
    </tr>
    <tr>
      <td>In     2005, <font color="blue"><font color="blue">international</font> sales accounted</font> for 37prca of our <font color="blue"><font color="blue">consolidated</font> revenues</font></td>
    </tr>
    <tr>
      <td>In     2004  and  2003,  <font color="blue"><font color="blue">international</font> sales accounted</font> for 34prca and 32prca of our     <font color="blue"><font color="blue">consolidated</font> revenues</font>, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>Revenue <font color="blue">growth outside</font> the United     States and Canada <font color="blue">depends on gaining</font> and <font color="blue">preserving market <font color="blue">acceptance</font></font> of our     devices and in <font color="blue">ovo administration</font> of <font color="blue">vaccine products</font> in markets outside the     <font color="blue"><font color="blue"><font color="blue">United States</font> </font>and Canada </font>to treat prevailing poultry diseases in those     markets</td>
    </tr>
    <tr>
      <td>Lack of market <font color="blue">acceptance</font> of our devices and in <font color="blue">ovo products</font> in     these <font color="blue">markets would <font color="blue"><font color="blue">materially</font> <font color="blue">adversely</font> affect</font></font> our <font color="blue">revenue growth</font></td>
    </tr>
    <tr>
      <td>Our     operating <font color="blue">expenses associated with <font color="blue">operations</font> outside</font> the <font color="blue"><font color="blue">United States</font> </font>and     Canada <font color="blue">historically</font> have <font color="blue">been <font color="blue">relatively</font> higher as</font> a percentage of revenues     than similar costs for <font color="blue">operations</font> inside the <font color="blue"><font color="blue">United States</font> </font>and Canada</td>
    </tr>
    <tr>
      <td>Accordingly, we believe that <font color="blue"><font color="blue">international</font> sales may</font> result in decreased     gross margins for Embrex</td>
    </tr>
    <tr>
      <td><font color="blue">International </font>sales are also subject to a variety of risks, including risks     arising from the following:           •   exchange rate risks (including <font color="blue">risk associated with</font> the <font color="blue">translation</font> of     our subsidiaries’ financial results into US Dollars and <font color="blue">transaction</font> risk),     tariffs, trade barriers and taxes;           •   adverse changes in local <font color="blue">investment</font> or exchange control <font color="blue">regulations</font>,     potential <font color="blue">restrictions</font> on the flow of <font color="blue">international</font> capital and the     <font color="blue">possibility</font> of confiscatory taxation, price controls or the taking or     <font color="blue">modification</font> of our <font color="blue">property rights by</font> a country in the exercise of its     <font color="blue">sovereignty</font>;           •   economic and <font color="blue">political conditions beyond</font> our control, including     country-specific conditions such as political instability, government     <font color="blue">corruption</font> and <font color="blue">civil unrest</font>;           •   the risk that we may not be granted a <font color="blue">renewal license due</font> to     <font color="blue">regulatory</font> changes or other <font color="blue">reasons <font color="blue">with respect</font></font> to <font color="blue">current product</font>     <font color="blue">registrations</font> in <font color="blue">certain foreign countries</font> that are subject to periodic     re-registration; and           •   trade <font color="blue">restrictions</font> and <font color="blue">economic embargoes imposed by</font> the <font color="blue"><font color="blue">United States</font> </font>    and other countries</td>
    </tr>
    <tr>
      <td>OUR FUTURE GROWTH ALSO DEPENDS ON THE DEVELOPMENT AND MARKET ACCEPTANCE OF     NEW PRODUCTS        In addition to <font color="blue">international</font> expansion, we need to develop and <font color="blue">market new</font>     products  to continue to <font color="blue">generate increased revenues</font> and growth of our     business</td>
    </tr>
    <tr>
      <td>We  currently  are  developing,  both  <font color="blue">independently</font> and in     collaboration with others, various products that <font color="blue">address poultry health</font> and     performance needs</td>
    </tr>
    <tr>
      <td>These products are being designed to be delivered in ovo     through the Inovoject® system or in <font color="blue">conjunction with</font> the Inovoject® system     and are in <font color="blue">various stages</font> of <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We may increase, decrease or     <font color="blue">eliminate funding</font> for any product under <font color="blue">development</font> at any time <font color="blue">depending on</font>     our <font color="blue">assessment</font> of our priorities, available funding, the <font color="blue">probability</font> that     the  product  can  be <font color="blue">successfully</font> <font color="blue">commercialized</font>, potential return on     <font color="blue">investment</font> and other factors</td>
    </tr>
    <tr>
      <td>There is no guarantee that any <font color="blue">new products</font>     will  be <font color="blue">successfully</font> developed and marketed</td>
    </tr>
    <tr>
      <td>In addition, we have not     initiated  the <font color="blue">regulatory</font> approval process for some of these potential     products,  and  we  <font color="blue">cannot assure</font> you that <font color="blue">regulatory</font> <font color="blue">approval will</font> be     obtained</td>
    </tr>
    <tr>
      <td>Our  inability  to develop <font color="blue">new products</font> or any delay in our     <font color="blue">development</font> of these <font color="blue"><font color="blue">products may</font> <font color="blue"><font color="blue">materially</font> <font color="blue">adversely</font> affect</font></font> our revenue     growth</td>
    </tr>
    <tr>
      <td>Because of a number of factors, a <font color="blue">new product may</font> not reach the     market                                           10     ______________________________________________________________________    [34]Table of <font color="blue">Contents       </font><font color="blue">without lengthy delays</font>, if at all</td>
    </tr>
    <tr>
      <td>Some of the factors that may affect our     <font color="blue">development</font> and marketing of <font color="blue">new products</font> include the following:           •   our research and <font color="blue">evaluations</font> of compounds and <font color="blue">new <font color="blue">technologies</font> may</font> not     <font color="blue">yield product opportunities</font>;           •   <font color="blue">potential product</font>s may involve extensive and time-consuming clinical     trials to <font color="blue">demonstrate safety</font> and <font color="blue">effectiveness</font>, and the results of such     trials are uncertain;           •   <font color="blue">potential product</font>s may require <font color="blue">collaborative partners</font> and we may be     unable to identify partners or <font color="blue">enter into arrangements on terms</font> acceptable     to us;           •   we may not be able to produce or contract for the <font color="blue">manufacture</font> of new     <font color="blue">products at</font> a cost or in quality or <font color="blue">quantities <font color="blue">necessary</font></font> to make them     <font color="blue"><font color="blue">commercially</font> viable</font>;           •   domestic and <font color="blue">international</font> <font color="blue">regulatory</font> approval of these <font color="blue">products may</font>     not be obtained or may be obtained <font color="blue">only with lengthy delays</font>;           •   we may not be able to <font color="blue">secure <font color="blue">additional</font> financing</font> that may be needed     to bring a <font color="blue">potential product</font> to market;           •   we may experience unexpected safety, <font color="blue">regulatory</font> or <font color="blue">efficacy concerns</font>     <font color="blue">with respect</font> to marketed products, whether or not <font color="blue">scientifically justified</font>,     leading to adverse public reaction, <font color="blue">product recalls</font>, withdrawals or     <font color="blue">declining sales</font>;           •   <font color="blue">marketing products</font> developed <font color="blue">jointly with</font> other <font color="blue">parties may</font> require     <font color="blue">royalty payments</font> or other <font color="blue">payments by us</font> to our co-developers, which may     <font color="blue"><font color="blue">materially</font> <font color="blue">adversely</font> affect</font> our <font color="blue">profitability</font>;           •   we may be unable to <font color="blue">accurately predict market requirements</font> and     <font color="blue">evolving standards</font>; and           •   we may not be able to attract and retain <font color="blue">sufficient numbers</font> of     qualified <font color="blue">development</font> personnel</td>
    </tr>
    <tr>
      <td>We  have  developed  and <font color="blue"><font color="blue">commercialized</font> two devices</font> that work with the     Inovoject® system: the Egg Remover® and Vaccine Saver®</td>
    </tr>
    <tr>
      <td>The Egg Remover® can     also be <font color="blue">used without</font> an Inovoject® system in <font color="blue">specific situations</font> where     customers do not need <font color="blue">injection services</font></td>
    </tr>
    <tr>
      <td>These two devices have had initial     success; however, there is no guarantee that <font color="blue">acceptance</font> of these devices     <font color="blue">will continue</font> to grow</td>
    </tr>
    <tr>
      <td><font color="blue">In December </font>2005, we filed for USDA <font color="blue">regulatory</font> approval <font color="blue">with respect</font> to our     in <font color="blue">ovo <font color="blue">coccidiosis</font> vaccine</font>, Inovocox^™</td>
    </tr>
    <tr>
      <td>Although this product is in the     <font color="blue">regulatory</font> review process, there is no assurance that USDA <font color="blue">approval will</font> be     obtained</td>
    </tr>
    <tr>
      <td><font color="blue">Marketing </font>this product in non-US countries will require us to     pursue separate approvals from foreign <font color="blue">regulatory</font> agencies</td>
    </tr>
    <tr>
      <td>We completed     <font color="blue">construction</font> of a vaccine <font color="blue">manufacturing</font> <font color="blue">facility</font>, Embrex Poultry Health, in     the first quarter of 2004 to <font color="blue">commercially</font> produce the Inovocox^™ vaccine</td>
    </tr>
    <tr>
      <td><font color="blue">Construction </font>costs for Embrex Poultry Health to date are <font color="blue">approximately</font> dlra14dtta7     million</td>
    </tr>
    <tr>
      <td>In addition to USDA approval for Inovocox^™, our <font color="blue">coccidiosis</font>     vaccine <font color="blue">manufacturing</font> <font color="blue">facility</font> must receive a separate USDA approval to     <font color="blue">manufacture</font> the Inovocox^™ vaccine</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that the <font color="blue">facility</font>     will receive USDA approval to <font color="blue">manufacture</font> Inovocox^™</td>
    </tr>
    <tr>
      <td>Delays in obtaining     either product or <font color="blue">manufacturing</font> <font color="blue">facility</font> approvals may <font color="blue">materially</font> <font color="blue">adversely</font>     affect  our  marketing  of,  and our ability to receive revenues from,     Inovocox^™</td>
    </tr>
    <tr>
      <td>Additionally, even if we receive USDA product and <font color="blue">facility</font>     approvals, we <font color="blue">cannot assure</font> you that Inovocox^™ <font color="blue">supplies will</font> be available,     that Inovocox^™ will be sold in <font color="blue">commercial quantities</font> or that <font color="blue">product sales</font>     will be sufficient to offset our <font color="blue">investment</font> in <font color="blue">development</font> of the product     and <font color="blue">construction</font> of the Inovocox^™ vaccine <font color="blue">manufacturing</font> <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>We have developed and <font color="blue">commercialized</font> AAC, which is <font color="blue">technology</font> that we use in     our Bursaplex® vaccine</td>
    </tr>
    <tr>
      <td>Bursaplex® has been sold in <font color="blue">commercial quantities</font>     during the <font color="blue">past six years</font>, and we currently have approval to sell it in 33     countries</td>
    </tr>
    <tr>
      <td>However, there is no assurance that supplies <font color="blue">will continue</font> to be     available  or  that the product <font color="blue">will continue</font> to be sold in commercial     quantities</td>
    </tr>
    <tr>
      <td>In May 2003, the USDA provided <font color="blue">regulatory</font> approval of Newplex^™, our in ovo     <font color="blue">Newcastle Disease </font>vaccine, within the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Newplex^™ vaccine is     <font color="blue">also based on</font> AAC <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We are now seeking <font color="blue">regulatory</font> approval for     Newplex^™ in key markets worldwide</td>
    </tr>
    <tr>
      <td>Although we have received approval to     sell Newplex™ in nine countries, there is no assurance that approvals in     other markets will be granted, that <font color="blue">supplies will</font> be available or that     Newplex^™ will be sold in <font color="blue">commercial quantities</font> in the <font color="blue"><font color="blue">United States</font> </font>or in     any of the other countries where approval has been obtained</td>
    </tr>
    <tr>
      <td>There can be no assurance that we will <font color="blue">successfully</font> complete the <font color="blue">development</font>     and <font color="blue">commercialization</font> of any <font color="blue">new products</font>, or that any of these <font color="blue">new products</font>     <font color="blue">will meet revenue</font> and <font color="blue">profit expectations</font> if developed and <font color="blue">commercialized</font></td>
    </tr>
    <tr>
      <td>11     ______________________________________________________________________    [35]Table of <font color="blue">Contents       </font>ECONOMIC FACTORS AFFECTING OUR CUSTOMERS MAY ADVERSELY AFFECT OUR FINANCIAL     RESULTS        Our <font color="blue">revenues principally come from leases</font> and sales to the <font color="blue">poultry industry</font></td>
    </tr>
    <tr>
      <td>If there is a <font color="blue">general economic decline</font> in that industry, our <font color="blue">operations</font> and     financial  <font color="blue">condition could</font> be <font color="blue">materially</font> and <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Also,     domestic and <font color="blue">global economic factors beyond</font> our control may <font color="blue">adversely</font> impact     our customers and, as a result, our revenues and earnings</td>
    </tr>
    <tr>
      <td>Examples of these     factors include the following:           •   <font color="blue">fluctuations</font> in the prices of energy and <font color="blue">poultry feed</font>;           •   <font color="blue">disease outbreaks</font> that <font color="blue">adversely</font> affect poultry production, including     <font color="blue">avian influenza</font>;           •   <font color="blue">market demand</font> for <font color="blue">poultry products</font>, including the supply and pricing     of <font color="blue">alternative proteins</font>;           •   costs to <font color="blue">comply with applicable laws</font> and <font color="blue">regulations</font>, including those     relating to environmental protection, food safety, market regulation and     <font color="blue">genetically modified organisms</font> or <font color="blue">ingredients</font>;           •   <font color="blue">product recalls</font> and related <font color="blue">adverse publicity</font> and <font color="blue">consumer reaction</font>;           •   access to foreign markets together with foreign economic conditions,     including currency <font color="blue">fluctuations</font> and trade <font color="blue">restrictions</font>; and           •   the extent to which our cost of products and operating expenses     increase faster than contractual price adjustments with our customers</td>
    </tr>
    <tr>
      <td>For example, if rising <font color="blue">poultry feed</font> prices increase the <font color="blue">production costs</font> of     <font color="blue">commercial poultry producers</font> or a <font color="blue">foreign government bans</font> the <font color="blue">importation</font> of     US chicken, these <font color="blue">producers may reduce poultry production</font></td>
    </tr>
    <tr>
      <td>This decreased     production could <font color="blue">adversely</font> impact our revenues, since a principal component     of  our  revenues are <font color="blue">fees charged</font> to customers for the number of eggs     injected or <font color="blue">processed by</font> Embrex devices</td>
    </tr>
    <tr>
      <td>WE FACE RISKS OF COMPETITION AND CHANGING TECHNOLOGY        The Inovoject® <font color="blue">system uses</font> a process that was patented in the <font color="blue"><font color="blue">United States</font> </font>    by the USDA in 1984</td>
    </tr>
    <tr>
      <td>We held the <font color="blue">exclusive license</font> to the <font color="blue">Sharma Patent </font>    until June 2002, when the <font color="blue">Sharma Patent </font>expired</td>
    </tr>
    <tr>
      <td>With the expiration of the     Sharma Patent, <font color="blue">competitive</font> in <font color="blue">ovo delivery systems</font> are being developed and     marketed</td>
    </tr>
    <tr>
      <td>Embrex is aware of <font color="blue">four companies</font> that are marketing in ovo     injection  systems  to  <font color="blue">poultry companies</font></td>
    </tr>
    <tr>
      <td>Although there has not been     widespread commercial <font color="blue">acceptance</font> of any of these <font color="blue">competing systems</font>, we are     aware of <font color="blue">direct <font color="blue">competition</font></font> for customers and limited <font color="blue">commercial placements</font>     by some of these companies, including with some of our customers</td>
    </tr>
    <tr>
      <td><font color="blue">Increased     </font><font color="blue"><font color="blue">competition</font> could</font> result in <font color="blue">lower prices</font> for our products, reduced demand     for our products and a <font color="blue">corresponding reduction</font> in our ability to recover     <font color="blue">development</font>,  <font color="blue">engineering</font>,  <font color="blue">manufacturing</font>  and  <font color="blue">service costs</font></td>
    </tr>
    <tr>
      <td>Also, a     <font color="blue">significant</font> portion of our revenues comes from a <font color="blue">relatively</font> small number of     customers</td>
    </tr>
    <tr>
      <td>If we lose one or more large <font color="blue">customers due</font> to <font color="blue">competition</font>, our     <font color="blue">revenues could</font> be <font color="blue">significant</font>ly lower</td>
    </tr>
    <tr>
      <td>Any of these <font color="blue">development</font>s could have     a  material  adverse effect on our business, results of <font color="blue">operations</font> and     <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">poultry vaccine</font> business is especially <font color="blue">competitive</font> and <font color="blue">dominated by</font> a     few large <font color="blue">companies with</font> an <font color="blue">established global presence</font></td>
    </tr>
    <tr>
      <td>In order for us to     expand our sales of in ovo vaccines, these <font color="blue">products must</font> be <font color="blue">commercially</font>     <font color="blue">accepted worldwide</font> and <font color="blue">compete effectively against</font> the vaccines of these     other  companies</td>
    </tr>
    <tr>
      <td>Our inability to compete <font color="blue">successfully</font> in the poultry     vaccine sector could <font color="blue"><font color="blue">materially</font> <font color="blue">adversely</font> affect</font> our <font color="blue">revenue growth</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> and potential <font color="blue">competitors</font> include <font color="blue">independent companies</font> that     specialize in bio<font color="blue">technology</font>, as well as major agricultural or <font color="blue">animal health</font>     companies, pharmaceutical companies, chemical companies, universities and     public and <font color="blue">private research organizations</font></td>
    </tr>
    <tr>
      <td>Many of these <font color="blue">competitors</font> are     well  established and have <font color="blue">substantially</font> greater marketing, financial,     <font color="blue">technological</font> and other <font color="blue">resources than</font> we have</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may succeed in     developing <font color="blue">technologies</font> and products that are more <font color="blue">effective than</font> any that     have been or are being developed by us or that could render our <font color="blue">technology</font>     and <font color="blue">products obsolete</font> or non-<font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>THE LOSS OF KEY CUSTOMERS COULD ADVERSELY AFFECT OUR FINANCIAL RESULTS        Historically,  a  <font color="blue">significant</font>  portion of our revenues has come from a     <font color="blue">relatively</font> small number of customers</td>
    </tr>
    <tr>
      <td>The only     other customer representing greater than 10prca of total <font color="blue"><font color="blue">consolidated</font> revenues</font>     is  Pilgrim’s,  representing 11prca and 12prca of <font color="blue">consolidated</font> 2005 and 2004     revenues, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>As with many of our customers, we have short-term     <font color="blue">contracts with</font> Tyson and Pilgrim’s</td>
    </tr>
    <tr>
      <td>Our <font color="blue">top three customers</font>, including Tyson     and Pilgrim’s, accounted for <font color="blue">approximately</font> 33prca and 36prca of our <font color="blue">consolidated</font>     2005 and 2004 revenues, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>We expect a similar level                                           12     ______________________________________________________________________    [36]Table of <font color="blue">Contents       </font>of customer <font color="blue">concentration</font> to continue in future years</td>
    </tr>
    <tr>
      <td>The <font color="blue">poultry market</font> is     highly concentrated, with the <font color="blue">largest poultry producers dominating</font> the     market</td>
    </tr>
    <tr>
      <td>For example, in 2005, Tyson and Pilgrim’s supplied <font color="blue">approximately</font> 23prca     and  15prca of all <font color="blue">broilers grown</font> in the <font color="blue">United States</font>, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">concentration</font> of our revenues with these large customers means factors     <font color="blue">affecting</font> those <font color="blue">customers also will impact</font> our revenues and earnings</td>
    </tr>
    <tr>
      <td>If we     lose  a  large  customer and fail to <font color="blue">add new customers</font> to <font color="blue">replace lost</font>     revenues, our operating results will be <font color="blue">materially</font> and <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Also,  if  these  <font color="blue">customers reduce</font> the number of eggs they <font color="blue">incubate at</font>     <font color="blue">hatcheries</font>, we will receive lower device <font color="blue">revenues since</font> our fees are based     on the number of <font color="blue">eggs injected</font></td>
    </tr>
    <tr>
      <td>IF  WE  LOSE THE PROTECTION OF OUR PATENTS AND PROPRIETARY RIGHTS, OUR     FINANCIAL RESULTS COULD SUFFER        Importance and Limitations of Patent and Proprietary Rights Protections        Some of our products and processes used to produce our products involve     <font color="blue">proprietary</font> rights, including patents</td>
    </tr>
    <tr>
      <td>We own some of the <font color="blue">technologies</font>     employed in these processes, and some are owned by others and licensed to     us</td>
    </tr>
    <tr>
      <td>The Inovoject® <font color="blue">system utilizes</font> a process that was <font color="blue">patented by</font> the USDA     in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>We held an <font color="blue">exclusive license</font> to the <font color="blue">Sharma Patent </font>    until it expired in June 2002</td>
    </tr>
    <tr>
      <td>We have supplemented the <font color="blue">Sharma Patent </font>with     <font color="blue">additional</font> US and foreign patents and have submitted <font color="blue">additional</font> patent     <font color="blue">applications</font> covering specific design features of the Inovoject® system, as     well  as  Embrex’s  Egg Remover® system and Vaccine Saver® option</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">competitors</font> or potential <font color="blue">competitors</font> may have filed for or received United     States and foreign patents and may obtain <font color="blue">additional</font> patents and <font color="blue">proprietary</font>     rights relating to in ovo <font color="blue">technology</font>, vaccines, uses and/or processes which     <font color="blue">may compete with</font> our <font color="blue">existing products</font> and our products under <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Accordingly, we <font color="blue">cannot assure</font> you that our patent <font color="blue">applications</font> will result     in patents being issued or that, if issued, the claims under our patents     will afford protection against <font color="blue">competitors</font> with similar <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We     cannot be sure that <font color="blue">others will</font> not obtain patents of different <font color="blue">technology</font>     that  we  would need to license or <font color="blue">circumvent</font> in order to practice our     <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>Even though we strive to take <font color="blue">appropriate action</font> to protect our     intellectual property, there is a risk that <font color="blue">competitive</font> systems currently     being developed and marketed could gain <font color="blue">acceptance</font> in the <font color="blue"><font color="blue">United States</font> </font>or     elsewhere</td>
    </tr>
    <tr>
      <td>We believe that <font color="blue">patent protection</font> of materials or processes we develop and     any products that may result from the research and <font color="blue">development</font> efforts of     our  <font color="blue">licensors</font>  and  us are important to the <font color="blue">commercial success</font> of our     products</td>
    </tr>
    <tr>
      <td>The loss of the protection of these patents and <font color="blue">proprietary</font> rights     could <font color="blue"><font color="blue">materially</font> <font color="blue">adversely</font> affect</font> our business and our <font color="blue">competitive</font> position     in the market</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent position</font> of <font color="blue">companies such as ours generally</font> is     <font color="blue">highly uncertain</font> and <font color="blue">involves complex legal</font> and factual questions</td>
    </tr>
    <tr>
      <td>Some of     the reasons for this <font color="blue">uncertainty</font> include the following:           •   To date, no consistent <font color="blue">regulatory</font> policy has emerged regarding the     breadth of claims allowed in bio<font color="blue">technology</font> patents</td>
    </tr>
    <tr>
      <td>Consequently, there can     be no assurance that patent <font color="blue">applications</font> relating to our products or     <font color="blue">technology</font> will result in patents being issued or that, if issued, the     patents will afford protection against <font color="blue">competitors</font> with similar <font color="blue">technology</font>;           •   Some <font color="blue">patent licenses</font> held by us may be <font color="blue">terminated upon</font> the occurrence     of <font color="blue">specified events</font> or become non-exclusive after a <font color="blue">specified period</font>;           •   <font color="blue">Companies </font>that obtain patents claiming products or processes that are     <font color="blue">necessary</font> for or useful to the <font color="blue">development</font> of our <font color="blue">products could bring legal</font>     <font color="blue">actions against us</font> claiming infringement (though we currently are not the     subject of any <font color="blue">patent infringement</font> claim);           •   Issuance of a <font color="blue">valid patent</font> does not prevent other companies from using     alternative, non-infringing <font color="blue">technology</font>, so we cannot be sure that any of our     patents (or <font color="blue">patents issued</font> to others and licensed to us) will provide     <font color="blue">significant</font> commercial protection;           •   We may not have the financial resources <font color="blue">necessary</font> to obtain patent     protection in some countries or to enforce any <font color="blue">patent rights</font> we may hold;           •   The laws of some foreign countries may not protect <font color="blue">proprietary</font> rights     to the <font color="blue">same extent as</font> the laws of the <font color="blue">United States</font>, and many companies have     <font color="blue">encountered</font> <font color="blue">significant</font> problems in protecting their <font color="blue">proprietary</font> rights in     these foreign countries;           •   We may be required to obtain <font color="blue">licenses from others</font> to develop,     <font color="blue">manufacture</font> or market our products</td>
    </tr>
    <tr>
      <td>We may not be able to obtain these     licenses on <font color="blue">commercially</font> reasonable terms, and we cannot be sure that the     <font color="blue">patents underlying</font> the <font color="blue">licenses will</font> be valid and enforceable; and           •   We also rely upon unpatented, <font color="blue">proprietary</font> <font color="blue">technology</font>, which we may not     be able to <font color="blue">protect fully</font> if others <font color="blue">independently</font> develop <font color="blue">substantially</font>     equivalent <font color="blue">proprietary</font> information or techniques, improperly gain access to     our <font color="blue">proprietary</font> <font color="blue">technology</font> or disclose this <font color="blue">technology</font> to others</td>
    </tr>
    <tr>
      <td>13     ______________________________________________________________________    [37]Table of <font color="blue">Contents       </font>We attempt to protect our <font color="blue">proprietary</font> materials and processes by relying on     <font color="blue">trade secret laws</font> and non-disclosure and <font color="blue">confidentiality <font color="blue">agreements</font> with</font> our     employees and other <font color="blue">persons with access</font> to our <font color="blue">proprietary</font> materials or     processes or who have licensing or <font color="blue">research arrangements with us</font></td>
    </tr>
    <tr>
      <td>We plan to     continue to use these <font color="blue">protections</font> in the future, but we cannot be sure that     these  <font color="blue">agreements</font>  will not be breached or that we would have adequate     remedies  for  any  breach</td>
    </tr>
    <tr>
      <td>Even  with  these <font color="blue">protections</font>, others may     <font color="blue">independently</font> develop or obtain access to these materials or processes,     which may <font color="blue"><font color="blue">materially</font> <font color="blue">adversely</font> affect</font> our <font color="blue">competitive</font> position</td>
    </tr>
    <tr>
      <td>If we are sued for infringing the patent or other <font color="blue">proprietary</font> rights of a     <font color="blue">third party</font>, we <font color="blue">could incur</font> substantial costs and diversion of <font color="blue">management</font>     and  technical  personnel, whether or not the <font color="blue">litigation</font> is ultimately     determined in our favor</td>
    </tr>
    <tr>
      <td>For a description of the patent <font color="blue">litigation</font>s in which we have <font color="blue">been involved</font>,</td>
    </tr>
  </tbody>
</table>